Abstract
Venous thromboembolism (VTE) is a common complication in patients with active cancer. Patients with cancer have a 4 to 7 times higher risk of developing VTE compared to the general population. VTE is associated with an annual recurrence rate of 21% and a bleeding risk of 12%. This often leads to the need for prolonged anticoagulation therapy and interruption of chemotherapy. Chemotherapy …